We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $915M
1-Year Est. Return 209.71%
This Fund
S&P 500
This Quarter Est. Return
-11.24%
1 Year Est. Return
+209.71%
3 Year Est. Return
+484.66%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$268M
AUM Growth
-$5.48M
Cap. Flow
+$37.9M
Cap. Flow %
14.12%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$30.2M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$7.71M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$169M 63.12%
5,500,007
– –
DSGN icon
2
Design Therapeutics
DSGN
$915M
$37.7M 14.03%
6,526,476
– –
MLYS icon
3
Mineralys Therapeutics
MLYS
$2.41B
$28.1M 10.47%
+1,794,600
New +$30.2M
SPRY icon
4
ARS Pharmaceuticals
SPRY
$591M
$26.1M 9.73%
4,012,903
+1,003,226
+33% +$7.71M
NKTX icon
5
Nkarta
NKTX
$167M
$4.73M 1.76%
1,333,333
– –
EFTR
6
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$2.39M 0.89%
272,885
– –

Similar funds

PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
SC
Sierra Capital Miami, Florida $918M AUM 8.25% 1-Year Est. Return
SI
Symmetry Investments St Helier, Jersey $913M AUM 30.59% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $913M AUM 11.84% 1-Year Est. Return
SAA
Southeast Asset Advisors Thomasville, Georgia $913M AUM 25.32% 1-Year Est. Return
GC
Greenvale Capital London, United Kingdom $912M AUM 34.2% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
FFL
Flat Footed LLC Wilson, Wyoming $920M AUM 86.47% 1-Year Est. Return

SR One Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, SR One Capital Management held 6 positions worth $268M, down 2% from $274M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

SR One Capital Management deployed $37.9M of net new capital in Q1 2023, opening 1 new position and adding to 1 existing holding. Its largest new stake was Mineralys Therapeutics: 1,794,600 shares worth $28.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • SR One Capital Management's largest Q1 2023 buy was Mineralys Therapeutics: 1,794,600 shares worth $28.1M.
  • SR One Capital Management added most to ARS Pharmaceuticals in Q1 2023, an estimated $7.71M increase.
  • SR One Capital Management's ten largest holdings make up 100% of its $268M portfolio in Q1 2023.
  • SR One Capital Management opened 1 new position and closed 0 in Q1 2023.
  • SR One Capital Management's portfolio value fell 2% quarter-over-quarter to $268M.

Based on SR One Capital Management's 13F filing for Q1 2023, filed 9 May 2023.